Catalent Micron Technologies Limited
Manufacture of basic pharmaceutical products · Swindon
ActiveUnited KingdomIncorporated 1980Private Limited Company
Financial position
Accounts to 2025-12-31 · GBP · Company accounts
Net assets
£25,210,965
Cash
£20,854,840
Turnover
£20,922,787
Profit / loss
£6,609,336
Current assets
£25,380,298
Creditors < 1 year
£3,161,750
Equity
£25,210,965
Average employees
68
Balance-sheet trend
GBP · companyFinancial statements
Selected figures from the best-ranked available filing for each period. Missing values remain unknown.
Some figures were read by AI from scanned accounts, so small errors are possible. View the filed accounts
| Reported figures | 2025-12-31Company · AI-read | 2024-06-30Company · AI-read |
|---|---|---|
| Balance sheet | ||
| Net assets | £25,210,965 | £18,601,629 |
| Equity | £25,210,965 | £18,601,629 |
| Share capital | £3 | £3 |
| Retained earnings | £24,929,771 | £18,320,435 |
| Assets | ||
| Fixed assets | £3,487,827 | £3,848,738 |
| Property, plant & equipment | £3,487,827 | £3,848,738 |
| Current assets | £25,380,298 | £17,224,316 |
| Cash at bank | £20,854,840 | £13,057,445 |
| Debtors | £4,162,121 | £3,966,387 |
| Stock | £363,337 | £200,484 |
| Liabilities | ||
| Creditors within one year | £3,161,750 | £1,937,684 |
| Provisions | £495,410 | £533,741 |
| Net current assets | £22,218,548 | £15,286,632 |
| Assets less current liabilities | £25,706,375 | £19,135,370 |
| Profit & loss | ||
| Turnover | £20,922,787 | £13,445,422 |
| Cost of sales | £5,910,725 | £3,830,298 |
| Gross profit | £15,012,062 | £9,615,124 |
| Administrative expenses | £8,239,912 | £5,369,368 |
| Operating profit | £6,772,150 | £4,245,756 |
| Interest receivable | £996,162 | £312,197 |
| Profit before tax | £7,768,312 | £4,557,953 |
| Tax | £1,158,976 | £13,097 |
| Profit / loss | £6,609,336 | £4,544,856 |
| Operating costs | ||
| Depreciation | £999,816 | £673,450 |
| Operating lease charges | £347,323 | £209,273 |
| Audit fees | £72,632 | £68,433 |
| People & pay | ||
| Average employees | 68 | 65 |
| Staff costs | £5,989,329 | £3,464,040 |
| Wages & salaries | £4,880,821 | £2,816,012 |
| Social security costs | £538,850 | £284,896 |
| Pension costs | £569,658 | £363,132 |
| Directors' remuneration | £309,483 | £162,509 |
| Source evidence | View filing | View filing |
From the accounts
What the accounts for 2025-12-31 say about themselves, read by AI from the scanned filing.
- Auditor
- Grant Thornton UK LLP
- Audit opinion
- Clean (unmodified)
- Immediate parent
- Catalent MTI Pharma Solutions Limited
- Ultimate parent
- Novo Holdings A/S
- Ultimate controlling party
- Novo Nordisk Fonden
- Accounts
- FRS 102
- Approved
- 2026-03-09, signed by G Elia
Turnover by segment (6)
- United Kingdom: 3,701,427 (2025-12-31)
- Europe: 17,017,037 (2025-12-31)
- Rest of the world: 204,323 (2025-12-31)
- United Kingdom: 2,932,372 (2024-06-30)
- Europe: 10,066,652 (2024-06-30)
- Rest of the world: 446,398 (2024-06-30)
Share classes (2)
- 3 Ordinary shares of £1.00 each
- 3 Ordinary shares of £1.00 each
Events after the year end (1)
- There have been no significant events affecting the company since the reporting date.
Secured borrowing
Registered charges, lenders and security interests.
Charges and related records
0 outstanding chargesShow 2 satisfied / released
All Assets · created 2014-04-09 · satisfied 2014-11-15
—
SatisfiedAll Assets · created 1990-08-17 · satisfied 2014-04-11
All monies
Satisfied